Update for Hemophilia Associations
BioMarin is a global pharmaceutical company with more than 20 years of experience in developing medicines for rare genetic conditions. BioMarin is pleased to update the community regarding our ongoing gene therapy clinical trial program in hemophilia A. BioMarin’s investigational gene therapy for hemophilia A